Effectiveness of tuberculosis chemotherapy correlates with resistance to Mycobacterium tuberculosis infection in animal models

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 7, 2011, Pages 1560-1566

  Ahmad, Zahoor ^a,d   Fraig, Mostafa M ^b   Pinn, Michael L ^a   Tyagi, Sandeep ^a   Nuermberger, Eric L ^a,c   Grosset, Jacques H ^a   Karakousis, Petros C ^a,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b University of Louisville School of Medicine   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d CSIR INDIAN INSTITUTE OF INTEGRATIVE MEDICINE   (India)

Author keywords

Antibiotics; Caseous necrosis; Chemotherapy; Chronic tuberculosis; Granuloma; Guinea pig; Hypoxia; Mouse; Persistence

Indexed keywords

ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC THERAPY; ARTICLE; BACTERICIDAL ACTIVITY; DRUG EFFICACY; EXPERIMENTAL GUINEA PIG; FEMALE; GRANULOMA; HISTOLOGY; LUNG; LUNG TUBERCULOSIS; LUNG WEIGHT; MOUSE; NONHUMAN; RELAPSE; SPLEEN WEIGHT; TREATMENT DURATION;

ANIMALS; ANTITUBERCULAR AGENTS; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY; FEMALE; GUINEA PIGS; MICE; MICE, INBRED BALB C; MYCOBACTERIUM TUBERCULOSIS; RECURRENCE; RODENT DISEASES; TUBERCULOSIS;

EID: 79958826429     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr188     Document Type: Article

References (35)

1. Fauci AS. Multidrug-resistant and extensively drug-resistant tuberculosis: the National Institute of Allergy and Infectious Diseases Research agenda and recommendations for priority research. J Infect Dis 2008; 197: 1493-8.
2. Vandiviere HM, Loring WE, Melvin I et al. The treated pulmonary lesion and its tubercle bacillus. II. The death and resurrection. Am J Med Sci 1956; 232: 30-7; passim.
3. Tomasz A, Albino A, Zanati E. Multiple antibiotic resistance in a bacterium with suppressed autolytic system. Nature 1970; 227: 138-40.
4. McCune RM Jr, McDermott W, Tompsett R. The fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. II. The conversion of tuberculous infection to the latent state by the administration of pyrazinamide and a companion drug. J Exp Med 1956; 104: 763-802.
5. Flynn J, Chan J. Animal models of tuberculosis. In: Rom W, Garay S, eds. Tuberculosis. Philadelphia: Lippincott Williams & Wilkins, 2004; 237-50.
6. McMurray DN. Disease model: pulmonary tuberculosis. Trends Mol Med 2001; 7: 135-7.
7. Lenaerts AJ, Hoff D, Aly S et al. Location of persisting mycobacteria in a guinea pig model of tuberculosis revealed by r207910. Antimicrob Agents Chemother 2007; 51: 3338-45.
8. Tsai MC, Chakravarty S, Zhu G et al. Characterization of the tuberculous granuloma in murine and human lungs: cellular composition and relative tissue oxygen tension. Cell Microbiol 2006; 8: 218-32.
9. Aly S, Wagner K, Keller C et al. Oxygen status of lung granulomas in Mycobacterium tuberculosis-infected mice. J Pathol 2006; 210: 298-305.
10. Karakousis PC, Williams EP, Bishai WR. Altered expression of isoniazid-regulated genes in drug-treated dormant Mycobacterium tuberculosis. J Antimicrob Chemother 2008; 61: 323-31.
11. Ahmad Z, Klinkenberg LG, Pinn ML et al. Biphasic kill curve of isoniazid reveals the presence of drug-tolerant, not drug-resistant, Mycobacterium tuberculosis in the guinea pig. J Infect Dis 2009; 200: 1136-43.
12. Ahmad Z, Nuermberger EL, Tasneen R et al. Comparison of the 'Denver regimen' against acute tuberculosis in the mouse and guinea pig. J Antimicrob Chemother 2010; 65: 729-34.
13. Klinkenberg LG, Sutherland LA, Bishai WR et al. Metronidazole lacks activity against Mycobacterium tuberculosis in an in vivo hypoxic granuloma model of latency. J Infect Dis 2008; 198: 275-83.
14. McMurray DN. Guinea pig model of tuberculosis. In: Bloom B, ed. Tuberculosis: Pathogenesis, Protection, and Control. Washington, DC: American Society for Microbiology, 1994; 135-47.
15. Ly LH, Russell MI, McMurray DN. Cytokine profiles in primary and secondary pulmonary granulomas of guinea pigs with tuberculosis. Am J Respir Cell Mol Biol 2008; 38: 455-62.
16. Cardona PJ. Revisiting the natural history of tuberculosis. The inclusion of constant reinfection, host tolerance, and damage-response frameworks leads to a better understanding of latent infection and its evolution towards active disease. Arch Immunol Ther Exp (Warsz) 2010; 58: 7-14.
17. Canetti G. Present aspects of bacterial resistance in tuberculosis. Am Rev Respir Dis 1965; 92: 687-703.
18. Leibert E, Rom W. Principles of tuberculosis management. In: Rom W, Garay S, eds. Tuberculosis. Philadelphia: Lippincott Williams & Wilkins, 2004; 713-28.
19. British Medical Research Council. A controlled trial of 3-month, 4-month, and 6-month regimens of chemotherapy for sputumsmear-negative pulmonary tuberculosis. Results at 5 years. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. Am Rev Respir Dis 1989; 139: 871-6.
20. Ha SJ, Jeon BY, Youn JI et al. Protective effect of DNA vaccine during chemotherapy on reactivation and reinfection of Mycobacterium tuberculosis. Gene Ther 2005; 12: 634-8.
21. Cardona PJ, Amat I, Gordillo S et al. Immunotherapy with fragmented Mycobacterium tuberculosis cells increases the effectiveness of chemotherapy against a chronical infection in a murine model of tuberculosis. Vaccine 2005; 23: 1393-8.
22. Ordway DJ, Shanley CA, Caraway ML et al. Evaluation of standard chemotherapy in the guinea pig model of tuberculosis. Antimicrob Agents Chemother 2010; 54: 1820-33.
23. Jayaram R, Shandil RK, Gaonkar S et al. Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 2004; 48: 2951-7.
24. Jayaram R, Gaonkar S, Kaur P et al. Pharmacokineticspharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 2003; 47: 2118-24.
25. Gumbo T, Dona CS, Meek C et al. Pharmacokineticspharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs. Antimicrob Agents Chemother 2009; 53: 3197-204.
26. Chan CY, Au-Yeang C, Yew WW et al. Postantibiotic effects of antituberculosis agents alone and in combination. Antimicrob Agents Chemother 2001; 45: 3631-4.
27. Chan CY, Au-Yeang C, Yew WW et al. In vitro postantibiotic effects of rifapentine, isoniazid, and moxifloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 2004; 48: 340-3.
28. Mitchison DA, Davies GR. Assessment of the efficacy of new anti-tuberculosis drugs. Open Infect Dis J 2008; 2: 59-76.
29. Rees RJ, Hart PD. Analysis of the host-parasite equilibrium in chronic murine tuberculosis by total and viable bacillary counts. Br J Exp Pathol 1961; 42: 83-8.
30. Shang S, Shanley CA, Caraway ML et al. The activity of TMC 207, rifampin, and pyrazinamide against Mycobacterium tuberculosis infection in guinea pigs. Antimicrob Agents Chemother 2011; 55: 124-31.
31. Ahmad Z, Pinn ML, Nuermberger EL et al. The potent bactericidal activity of streptomycin in the guinea pig model of tuberculosis ceases due to the presence of persisters. J Antimicrob Chemother 2010; 65: 2172-5.
32. Dessau FI, Yeager RL, Burger FJ et al. Pyrazinamide (aldinamide) in experimental tuberculosis of the guinea pig. Am Rev Tuberc 1952; 65: 519-22.
33. Steenken W Jr, Wolinsky E. The antituberculous activity of pyrazinamide in vitro and in the guinea pig. Am Rev Tuberc 1954; 70: 367-9.
34. Ahmad Z, Fraig MM, Bisson GP et al. Dose-dependent activity of pyrazinamide in animal models of intracellular and extracellular tuberculosis infections. Antimicrob Agents Chemother 2011; 55: 1527-32.
35. Zhang Y, Mitchison D. The curious characteristics of pyrazinamide: a review. Int J Tuberc Lung Dis 2003; 7: 6-21.